文献速递生殖医学妇科

自体富血小板血浆用于卵巢组织移植:一项初步临床试验

Ovarian Tissue Transplantation Using Autologous Platelet-Rich Plasma: A Pilot Clinical Trial.
PubMed 文献 · J Minim Invasive Gynecol · 2026-02-01

本研究为单中心前瞻性试点队列研究,纳入5例接受自体富血小板血浆(PRP)辅助腹腔镜卵巢组织原位再植入的患者,与19例历史对照比较。结果显示无手术并发症或PRP不良反应,PRP组卵巢功能恢复中位时间3个月,短于对照组,1例妊娠并活产。结论认为PRP是可行且安全的辅助手段,可能促进卵巢功能恢复。

要点

  • 自体PRP辅助卵巢组织移植未观察到手术并发症或PRP相关不良反应。
  • PRP组卵巢功能恢复中位时间3个月,显著短于未使用PRP的历史队列。
  • 1例患者术后3个月妊娠并活产,提示PRP可能改善生殖结局。

核心结论

  • 自体PRP是卵巢组织原位移植中可行且安全的辅助手段,可能促进卵巢功能恢复。

研究设计与样本

  • 单中心、干预性、试点、前瞻性队列研究,纳入5例连续合格患者,与19例历史对照比较。

主要发现

  • PRP组取组织时平均年龄30岁(范围27-31),移植时38岁(36-41);非PRP组分别为33岁(24-34)和41岁(34-42)。
  • 研究期间无术中或术后并发症,也无PRP使用相关不良反应。
  • PRP组所有患者卵巢功能恢复,中位时间3个月(范围1-6),显著短于非PRP组。
  • 实验组1例患者术后3个月妊娠,报告时已活产1次。

关键数值与推荐

  • 自体PRP 10 mL经葡萄糖酸钙转化为凝胶,覆盖于冻融卵巢组织碎片后植入卵巢皮质和/或腹腔创建的袋中。

临床怎么用

  • 在腹腔镜卵巢组织原位再植入中,可考虑使用自体PRP凝胶作为辅助,可能缩短卵巢功能恢复时间。

局限性

  • 试点研究样本量小(PRP组5例),采用历史对照,结论需更大规模随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the feasibility and safety of using autologous platelet-rich plasma (PRP) during laparoscopic orthotopic reimplantation of cryopreserved ovarian tissue. DESIGN: Single-center, interventional, pilot, prospective, cohort study. SETTING: Tertiary university hospital (IRCCS-Azienda Ospedaliero-Universitaria di Bologna-Policlinico Sant'Orsola). PARTICIPANTS: Five eligible consecutive patients, who previously cryopreserved ovarian tissue before chemo(radio) therapy for oncologic diseases and were scheduled for orthotopic reimplantation with the use of autologous PRP to treat iatrogenic premature ovarian failure, were compared with a historical cohort of 19 similar patients who underwent orthotopic reimplantation without the use of autologous PRP. INTERVENTIONS: Before surgery, autologous PRP (10 mL) was transformed into gel using calcium gluconate. Autotransplantation was performed by standard four-port laparoscopy, creating pockets in the ovarian cortex and/or peritoneal cavity to insert frozen-thawed ovarian tissue fragments covered by gelled PRP. Pre-, intra-, and postoperative data were collected (characteristics of the study population, adverse reactions, operative time, surgical complications, menstrual resumption). RESULTS: Study outcomes included: rate of adverse reactions, rate of intra- and postoperative surgical complication, total intraoperative time, rate of restored endocrine function, and median (absolute range) time to first menses (expressed in months) during follow-up. The mean (range) age at ovarian tissue retrieval and at transplantation were 30 (27-31) and 38 (36-41) years for the PRP group, and 33 (24-34) and 41 (34-42) years for the non-PRP group. During the study period, no intra- and postoperative complication nor adverse reaction to PRP use was observed. All patients treated with PRP experienced resumption of regular ovarian function after a median (range) period of 3 (1-6) months, with a significant shorter time in the PRP group. One patient in the experimental group conceived 3 months after surgery and had one live birth at the time of this report. CONCLUSION: Autologous PRP appears to be a feasible and safe adjunct in orthotopic ovarian tissue transplantation, potentially enhancing the restoration of ovarian function.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Vicenti R, Doglioli M, Raffone A, et al. Ovarian Tissue Transplantation Using Autologous Platelet-Rich Plasma: A Pilot Clinical Trial. J Minim Invasive Gynecol. 2026. PMID: 41633485. doi:10.1016/j.jmig.2026.01.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。